BackIRIDEX Overview

IRIDEX Current Assets

Latest current assets for IRIX: $25M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$24.58M
↓ 15.60% YoYΔ $-4.54M vs prior year quarter

Peer average

Loading

IRIDEX Current Assets History

Loading

IRIDEX vs. peers: Current Assets Comparison

Loading

IRIDEX Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

IRIDEX (IRIX) FAQ

As of the most recent data (April 2026), IRIX shows a current assets of $25M. That compares with $29M in the prior-year period — down 15.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IRIX's current assets is now $25M (was $29M) — a 15.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether IRIDEX is outperforming or lagging.

Tracking IRIX's current assets over time shows whether IRIDEX is scaling, shrinking, or reshaping that part of the business. The current reading is $25M That compares with $29M in the prior-year period — down 15.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has IRIDEX's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $25M) with ownership activity and broader fundamentals.

IRIDEX's current assets is $25M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.